REGQUALITYREVIEW

Evidence for systems that carry regulated work.

Provider capability evidence record

AmpleLogic and CAPA

What the current official record does—and does not—establish about AmpleLogic for CAPA.

What the source record establishes

AmpleLogic provides pharmaceutical-focused low-code applications for electronic quality management, regulatory information, documents, training, logs, laboratory, and manufacturing-adjacent processes.

The maintained taxonomy connects that documented market position to CAPA. This page keeps the claim at the level supported by the source: AmpleLogic presents an offering relevant to this work. It does not silently convert a product description into an observed result, a conformity finding, or a universal recommendation.

Current fit signal: Pharmaceutical manufacturers evaluating a configurable platform across quality, regulatory, and adjacent operations rather than a single point application.

What CAPA means in this market

CAPA should be evaluated as an operating chain rather than a feature label. The chain begins with a named business condition and governed input, passes through configured logic and accountable review, produces an output or action, handles exceptions, and preserves enough evidence for another person to reconstruct the decision later.

Audit, inspection, and evidence readiness

Risk that the organization cannot retrieve a coherent, accurate, and reviewable evidence chain for an auditor, inspector, certification body, notified body, or internal governance review without manual reconstruction.

Supplier quality and external operations

Risk that suppliers, laboratories, contract manufacturers, service providers, and other external parties are selected, qualified, monitored, changed, and governed without sufficient evidence or connection to product and process risk.

Complaints, post-market quality, and safety handoffs

Risk that complaints, adverse-event indicators, product-quality complaints, vigilance, field actions, recalls, post-market surveillance, and regulatory reporting are delayed or fragmented across quality, safety, medical, regulatory, and commercial systems.

Who owns the decision

A capability can be technically available while operating ownership remains fragmented. The evaluation should name the person accountable for policy or business interpretation, the person responsible for configuration and data, the reviewer with authority to resolve exceptions, the approver of release or action, and the owner of monitoring and retirement.

AmpleLogic should be asked to distinguish what the product decides, what it recommends, what it merely displays, and what remains an organizational judgment. A generic “human in the loop” statement is inadequate unless the human has time, context, evidence, and authority.

Evidence package to request from AmpleLogic

  • The exact product and package proposed, with a dated list of native, integrated, partner, service, and customer-owned components.
  • A representative input set, its authoritative source, permitted use, quality checks, and version history.
  • The configured workflow from intake through review, exception, approval, action, retention, and export.
  • A normal result and at least two difficult exceptions, including one caused by missing or contradictory evidence.
  • Role and access definitions for configuration, review, approval, override, monitoring, and administration.
  • An implementation map naming integrations, migrations, customer work, provider work, services, test environments, and release gates.
  • A retained decision record showing source, logic or model version, user action, timestamps, disposition, and downstream effect.
  • A measurement plan with baseline, observation period, population, error threshold, exclusions, and stop condition.

Demonstration script

  1. Which exact AmpleLogic product, edition, module, service, and geography support CAPA?
  2. What source data, content, rules, and integrations does AmpleLogic require before the workflow can begin?
  3. Where does human judgment enter, and which person can approve, reject, override, or stop the CAPA workflow?
  4. How does the proposed configuration handle missing data, conflicting evidence, changed rules, and an expired or revoked approval?
  5. What record preserves inputs, transformations, user actions, exceptions, outputs, timestamps, and downstream consequences?
  6. Which parts are native, partner-delivered, service-delivered, or left to the customer?
  7. What can be exported at implementation, audit, renewal, migration, and exit?
  8. Which observation would falsify the current fit hypothesis for AmpleLogic?
  9. Can a user retrieve the current and historical records for a process, product, site, supplier, or quality issue with their relationships intact?
  10. Which audit-planning, execution, finding, response, commitment, and follow-up records are maintained natively?
  11. How are privileged inspection workspaces or temporary reviewer access created, monitored, and removed?
  12. Can management-review metrics be traced back to underlying records and definitions rather than static presentation slides?

Use the same scenario with every finalist. Let the provider explain differences in architecture, but keep the business condition, required evidence, exception, and expected decision record constant. That makes the evaluation comparable without pretending that unlike products should receive one synthetic score.

Failure modes and boundary conditions

  • a polished normal path that hides missing or contradictory evidence
  • an automation step that exceeds the user's authority
  • a score or generated explanation that cannot be traced to a source and version
  • an exception that disappears into email or an unexportable activity log

Official pages do not establish the maturity or depth of every module, validation evidence, deployment scale, integration performance, or the governance required for low-code configuration.

A buyer should also distinguish absence of public evidence from evidence of absence. If AmpleLogic has not publicly documented a required detail, the correct status is “not established in this review” until a current, attributable source or direct observation resolves it.

Authority and standards context

FDA drug CGMP

eQMS products organize records supporting drug CGMP processes, but software boundaries must align with manufacturing, laboratory, ERP, MES, and supplier systems. A feature list alone cannot establish that regulated processes are controlled.

Interpretation boundary: The regulation defines CGMP obligations, not a commercial eQMS specification. Buyers must map their own records and controls to applicable sections and connected systems.

This mapping identifies a workflow that may help organize evidence. It does not state that AmpleLogic conforms to, complies with, or is certified against the authority.

ISO 13485:2016

The standard is a central organizing reference for medical-device QMS design and is incorporated into the U.S. QMSR. Buyers need systems that can express their own processes and evidence without treating a vendor template as the standard itself.

Interpretation boundary: ISO publishes the standard and does not certify organizations or software. The public ISO page summarizes scope; detailed requirements are in the licensed standard.

This mapping identifies a workflow that may help organize evidence. It does not state that AmpleLogic conforms to, complies with, or is certified against the authority.

ICH Q10

Q10 provides an operating model that crosses organizational and software boundaries. An eQMS can support records and coordination, but buyers must test how the system connects monitoring, investigation, CAPA, change, knowledge, and management oversight.

Interpretation boundary: ICH Q10 is a quality-system model, not a software certification or prescribed workflow. Regulatory adoption and product-specific obligations must be checked in the relevant jurisdiction.

This mapping identifies a workflow that may help organize evidence. It does not state that AmpleLogic conforms to, complies with, or is certified against the authority.

Comparable records to inspect

The following organizations also have current official positioning mapped to CAPA. Inclusion is a research pathway, not a shortlist or claim of equivalence.

  • Ennov — Integrated Quality And Regulatory Platform with documented positioning relevant to CAPA
  • Generis CARA — Integrated Quality And Regulatory Platform with documented positioning relevant to CAPA
  • IQVIA SmartSolve — Integrated Quality And Regulatory Platform with documented positioning relevant to CAPA
  • Veeva Systems — Integrated Quality And Regulatory Platform with documented positioning relevant to CAPA
  • Arena QMS — Medical-Device Quality And Product-Lifecycle Platform with documented positioning relevant to CAPA
  • AssurX — Configurable QMS With Life-Sciences Offering with documented positioning relevant to CAPA

Official authority sources

The following primary authority pages support the standards context used in this record. They define an evaluation boundary; they do not endorse AmpleLogic or establish product conformity.

FDA drug CGMP

Open the official authority source and confirm the current text, effective date, scope, and organization-specific applicability before relying on this mapping.

ISO 13485:2016

Open the official authority source and confirm the current text, effective date, scope, and organization-specific applicability before relying on this mapping.

ICH Q10

Open the official authority source and confirm the current text, effective date, scope, and organization-specific applicability before relying on this mapping.

Conditional conclusion

AmpleLogic belongs in deeper evaluation for CAPA when its documented integrated quality and regulatory platform operating model matches the buyer's real workflow, the proposed package contains the required components, and a representative test produces reviewable evidence through normal and exception paths. The conclusion should be reversed or narrowed when the product boundary, source data, authority mapping, integration burden, human decision rights, exportability, or measured result does not meet the stated approval conditions.

Official provider source: AmpleLogic.

Record date: 2026-07-19T13:51:00.000Z. The date records the maintained source review, not an independent product test.

Editorial boundary: RegQuality Review is not a regulator, certification body, law firm, or validation authority. Its records support research and decision review; they do not establish compliance for an organization, system, release, configuration, or intended use.

Methodology · Submit a source-backed correction